Description
Seeking adults with advanced or metastatic gastrointestinal stromal tumor (GIST) with a documented KIT gene mutation for a study of an investigational drug taken in combination with ripretinib.
Overview
Participants in this study will get the investigational drug and ripretinib in 28-day cycles. During the first cycle there will be 3 study visits. Every cycle after that there will be only one study visit.
What we're hoping for
We are studying whether adding an investigational drug to ripretinib treatment for advanced or metastatic gastrointestinal stromal tumor (GIST) with a documented KIT gene mutation is safe and effective.
Additional Information
ClinicalTrials.gov Identifier: NCT05957367